SCHEMBL21166372

SCHEMBL21166372

C=CC(=O)NCC(C)(CCCCCC)CCCCCC

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ZDHHC20 Q5W0Z9 1/20 0.59
ZDHHC2 Q9UIJ5 1/20 0.59
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
FAAH O00519 1/20 0.40
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EPHX1 P07099 6/20 0.36
CES2 O00748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18737457 1.00 ZDHHC20 (0.59) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL21166382 1.00 ZDHHC20 (0.59) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL20927031 0.98 ZDHHC20 (0.57) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL19176499 0.98 ZDHHC20 (0.57) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL20216150 0.97 ZDHHC20 (0.56) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL24486557 0.94 ZDHHC20 (0.56) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL25469140 0.93 ZDHHC20 (0.53) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL19069142 0.90 ZDHHC20 (0.50) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL18867110 0.87 ZDHHC20 (0.59) ZDHHC20ZDHHC2CNR1CNR2FAAH
SCHEMBL24690197 0.87 ZDHHC20 (0.50) ZDHHC20ZDHHC2CNR1CNR2FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11351168-B1 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE CAR LLC (BM) 2022-06-07 US disclosed
US-10618902-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases CELGENE CAR LLC (BM) 2020-04-14 US disclosed
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218220-A1 HETEROARYL COMPOUNDS AND USES THEREOF PRKACA, PRKDC, AURKC ZDHHC20 1626/4885ZDHHC2 2316/4885CNR1 2968/4885
US-11351168-B1 2,4-disubstituted pyrimidines useful as kinase inhibitors DCK, CDK2, DTYMK ZDHHC20 2150/4885ZDHHC2 2325/4885CNR1 3066/4885
US-10618902-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases PDXK, DCK, DTYMK ZDHHC20 3125/4885ZDHHC2 3531/4885CNR1 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.